Accès à distance ? S'identifier sur le proxy UCLouvain
Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA.
Primary tabs
- Open access
- 1.79 M
Document type | Article de périodique (Journal article) – Article de recherche |
---|---|
Access type | Accès libre |
Publication date | 2017 |
Language | Anglais |
Journal information | "Journal of controlled release" - Vol. 266, p. 287-300 (2017) |
Peer reviewed | yes |
Publisher | Elsevier Science Publishers ((Netherlands) Amsterdam) |
issn | 0168-3659 |
e-issn | 1873-4995 |
Publication status | Publié |
Affiliation | Ghent University Hospital - Department of Pathology |
MESH Subject | Animals ; Cancer Vaccines ; Cytidine ; Dendritic Cells ; Female ; Immunotherapy ; Lipid A ; Lipids ; Mice, Inbred C57BL ; Neoplasms ; RNA, Messenger ; Toll-Like Receptors |
Keywords | 5-Methylcytidine (PubChem CID: 92918) ; Adjuvant ; CFSE (PubChem CID: 16211581) ; Cholesterol (PubChem CID: 5997) ; DOPE (PubChem CID: 9546757) ; DOTAP (PubChem CID: 6437371) ; Dendritic cell ; Lipid nanoparticle ; MPLA ; MPLA (PubChem CID: 5043498) ; Pseudouridine (PubChem CID: 57369533) ; SIINFEKL (PubChem CID: 71311993) ; Type I interferon ; mRNA vaccination |
Links |
Bibliographic reference | Verbeke, Rein ; Lentacker, Ine ; Wayteck, Laura ; Breckpot, Karine ; Van Bockstal, Mieke ; et. al. Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA.. In: Journal of controlled release, Vol. 266, p. 287-300 (2017) |
---|---|
Permanent URL | http://hdl.handle.net/2078.1/224354 |